JOUNCE THERPEUTC CM

Jounce Therapeutics Appoints Robert Iannone, M.D., M.S.C.E., to its Board of Directors

23 Jan 2020 08:00:10 By Nasdaq GlobeNewswire

Jounce Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

09 Jan 2020 08:00:17 By Nasdaq GlobeNewswire

Jounce Therapeutics to Present New Data on a Potential Predictive Biomarker from the Vopratelimab ICONIC Trial at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting

19 Dec 2019 15:00:17 By Nasdaq GlobeNewswire

Jounce Therapeutics Reports Third Quarter 2019 Financial Results

07 Nov 2019 06:30:00 By Nasdaq GlobeNewswire

Jounce Therapeutics to Present Safety and Preliminary Efficacy Data on JTX-4014 and a Trials in Progress Poster for the Vopratelimab EMERGE Study at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting

05 Nov 2019 08:05:00 By Nasdaq GlobeNewswire

Jounce Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call on Thursday, November 7, 2019

31 Oct 2019 08:00:42 By Nasdaq GlobeNewswire

Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting

01 Oct 2019 18:01:01 By Nasdaq GlobeNewswire

Jounce Therapeutics Names Jacquelyn Fahey Sandell as Chief Legal Officer and Corporate Secretary

17 Sep 2019 08:02:15 By Nasdaq GlobeNewswire

Jounce Therapeutics to Present at Upcoming Investor Conferences in September

28 Aug 2019 08:00:41 By Nasdaq GlobeNewswire

Jounce Therapeutics Reports Second Quarter 2019 Financial Results

07 Aug 2019 06:30:21 By Nasdaq GlobeNewswire

Jounce Therapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019

31 Jul 2019 08:01:53 By Nasdaq GlobeNewswire

Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation

23 Jul 2019 16:00:11 By Nasdaq GlobeNewswire

Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer

18 Jun 2019 08:00:37 By Nasdaq GlobeNewswire

Jounce Therapeutics to Present at Upcoming Investor Conferences in June

11 Jun 2019 08:00:30 By Nasdaq GlobeNewswire

Jounce Therapeutics Reports First Quarter 2019 Financial Results

08 May 2019 06:31:01 By Nasdaq GlobeNewswire

Jounce Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019

01 May 2019 08:00:10 By Nasdaq GlobeNewswire

Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual Meeting

03 Apr 2019 08:02:00 By Nasdaq GlobeNewswire

Jounce Therapeutics Reports Improved PFS and OS Associated with Vopratelimab (JTX-2011) Treatment Emergent Biomarker at the 2019 American Association for Cancer Research (AACR) Annual Meeting

02 Apr 2019 13:02:00 By Nasdaq GlobeNewswire

Jounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

06 Mar 2019 06:30:10 By Nasdaq GlobeNewswire

Jounce Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference

04 Mar 2019 08:01:57 By Nasdaq GlobeNewswire